Kanc: I have to agree with you and Mr. Tibbs 100%. Look at it this way. If CYGX hadn't stumbled upon the method to produce synDNA, would this company still exist? They have no money. They haven't been able to advance a single compound even to apply for an IND. No partner is going to magically help them out based on pre-clinical studies. Basically they were down to a single avenue to survival....synDNA. They got Aldevron to test and confirm the efficacy of a synDNA vaccine sometime in the fall of 2005. Instead of moving full speed ahead to aquire land and build a facility, the ultra conservative CEO slowly and methodically took his time to find a plot of land in Houston. They delayed that decision at least 6 months longer than should have been needed. While they were looking for some dirt they apparently didn't have the money or the foresight to get an architect working on preliminary blueprints, because here we are 18 months later and they still have not finalized the plans or broken ground. If we're lucky they'll break ground by summer. If we're lucky. They'll have between $1.5 and $2.0 million in he bank by then. The facility will cost somewhere in the vacinity of $3 million. They still need to pay salaries. Which means another round of PPO sales will be needed. With the stock trading near 40 cents a share Malcolm would be lucky to get 25 cents a share, which means he needs to sell off a 10 million share block just to get us to the end of the year. If he can find some buyers. Some of the big holders have held steady, but I have to think they might be getting a little impatient at this point and might not want to sink any more capital into this company. Who knows, maybe I'm wrong. Still, my point is that with an experienced CEO with business acumen that facility would already be built, would already be FDA approved and CYGX would have 2 full time sales people travelling the globe trying to gain significant contracts for synDNA sales and they would be speaking or presenting at every conference related to Vaccines or DNA Therapeutics. Lets face it, we all expected a lot more progress to come from that GE announcement at the end of 2005. Has that gained us anything that you know of, other than we have a reliable supplier of reagents. Has it gotten us any Federal grants? Has it gotten us any licensing deals? Has it added to our bottom line in any way? I don't see it. I admit, I was taken in. I figured with GE in our corner we'd make fast progress. That has not proven to be the case. And we don't hear anything more about our involvement with GE, do we? So, I will let Marcus Aurelius and JJ wax poetic about how Malcolm is such a nice guy, etc. etc. I'm sure he is. And I'm sure he is a wise and cautious patent lawyer. But a CEO he is not. Which is why our share price is down 70% in a year and why we have still not broken ground on a relatively simple industrial building almost 18 months after they realized it would be necessary to become a viable supplier of synDNA. Malcolm's legacy? He kept the doors open during some very lean times. He enticed some talented people to come aboard. But he was too cautious when bold action was needed. And his decisions created more lawsuits than revenue, which is another reason the stock is mired in quicksand like it is. So I hope that rumors of a new CEO come to fruition soon.
AI
Market Data 
Markets 
